Clinical Edge Journal Scan

Whole blood viscosity as a biomarker for distant metastasis and survival in HCC


 

Key clinical point : High diastolic whole blood viscosity (WBV) may serve as a new independent factor associated with extrahepatic metastasis and poor survival in patients with hepatocellular carcinoma (HCC).

Main finding: After adjusting for confounding variables, high diastolic WBV was independently associated with extrahepatic metastasis (adjusted odds ratio, 23.41; P < .001) and poor survival (adjusted hazard ratio, 3.81; P < .001) and significantly predicted extrahepatic metastasis at an optimal cutoff of 16 cP (area under the receiver operating characteristic curve, 0.768; P < .001).

Study details: Findings are from a pilot retrospective study including 181 patients with HCC, of which 148 were treatment-naïve having preserved liver function and 33 received nivolumab.

Disclosures: The study was sponsored by Young Medical Scientist Research Grant through the Daewoong Foundation and the Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea. The authors did not declare any conflict of interests.

Source: Han JW et al. PLoS ONE. 2021 Dec 2. doi: 10.1371/journal.pone.0260311 .

Recommended Reading

Complete response after TACE predicts survival for new HCC patients
Federal Practitioner
Atezolizumab plus bevacizumab benefits subset of HCC patients as first-line therapy
Federal Practitioner
Reduction hepatectomy plus multidisciplinary therapy improves HCC outcomes
Federal Practitioner
Transarterial chemoembolization plus percutaneous microwave ablation optimizes outcomes for unresectable HCC
Federal Practitioner
Lenvatinib tops sorafenib for progression-free survival in HCC
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC December 2021
Federal Practitioner
No survival benefits with first-line nivolumab vs sorafenib in advanced HCC
Federal Practitioner
Atezolizumab + bevacizumab shows long-term benefits over sorafenib for unresectable HCC
Federal Practitioner
HAIC-FO outperforms sorafenib against advanced HCC in phase 3
Federal Practitioner
Radiologic response to TACE-RT as a prognostic factor in advanced HCC with macroscopic vascular invasion
Federal Practitioner